APLS Apellis Pharmaceuticals Inc.

+0.23  (+1%)
Previous Close 18.65
Open 18.66
Price To Book 7.4
Market Cap 1193014116
Shares 63,189,307
Volume 179,652
Short Ratio
Av. Daily Volume 527,829

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
Discovery (APL2-201)
Complement-dependent Nephropathies (CDN)
Phase 2 data presented at ASH 2018.
APL-2 subcutaneous
Auto-immune Hemolytic Anemia (AIHA)
Phase 1b trial ongoing.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 resumption of enrolment announced March 4, 2019. Enrolment to be completed 1Q 2020.
Geographic atrophy (GA) associated with age-related macular degeneration (AMD)
Phase 3 data due 4Q 2019.
APL-2 subcutaneous
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
Paroxysmal Nocturnal Hemoglobinuria

Latest News

  1. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  2. Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
  3. Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  4. Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
  5. Apellis resumes trial after safety investigation
  6. Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
  7. Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
  8. Apellis lands as much as $250M in financing from drug development company
  9. Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
  10. Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  11. Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
  12. Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
  13. Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe
  14. Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher
  15. Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
  16. Is Apellis Pharmaceuticals, Inc. (APLS) A Good Stock To Buy?
  17. Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy